Conservative treatment for high-risk NMIBC failing BCG treatment: who benefits from adding electromotive drug administration (EMDA) of mitomycin C (MMC) to a second BCG induction cycle?

World J Urol · 2023 · PMC10188396 · PMID 36971825

Europe PMC DOI

hedged sentence

0.0800

closest p · 1.6× alpha

0.0800

boldest claim

The sentences

did not reach statistical significancep = 0.08so close (0.05 < p ≤ 0.1)

1 ) showed a clear advantage for sequential treatment, which was close but did not reach statistical significance ( p = 0.08) for recurrent HG disease whereas it was statistically significant when also low-grade recurrences were considered ( p = 0.03).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.